about
STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liverHepatocellular carcinoma: Where there is unmet needMetallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosisXmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinomaEpirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinomaSorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis.Targeted therapy in hepatocellular carcinomaChemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma CellsGITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo.Downregulation of ANP32B exerts anti-apoptotic effects in hepatocellular carcinomaAnti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment.The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expressionHBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.Mouse models for liver cancer.Treatment of hepatocellular carcinoma: present and future.Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis.Developments in cancer vaccines for hepatocellular carcinoma.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives
P2860
Q27000742-FBB48801-6781-4181-966C-B43168C1B78FQ28084046-B2C6953C-070E-4555-9956-60A26F78C6A1Q28384683-D492B89D-96B8-47E2-8336-C99612D451BDQ28540910-4A9789F5-CC15-4FCB-90EA-AED453089E59Q33412612-B7E9EE0E-EE5B-4965-816B-A61CEC940DF7Q33614172-CF952CB5-4B09-45AB-985C-F5FE03806CE4Q34013776-A69E9A34-F466-4B1F-8A21-3534B4659A87Q34241371-1DA01215-ECE2-42F9-929D-B845D4C57AB3Q34827556-9AA3D2EE-D72F-4FB4-9D89-E219CD452795Q35167959-C738C085-AB6F-4A53-93A4-4B3AEB23C9F2Q35207561-653DD253-11D5-4B9C-B15E-C3AB81EB8500Q35740345-B59AEFFC-D41B-49F8-934D-1D728CF15226Q35914942-45320F1D-A76E-4273-86CF-3FE47EE80620Q36226732-D0CD74C0-986A-4336-AD02-BB88523DDB9BQ36256549-0AD4BC0A-6E47-4CB6-8DA9-97FD0AE8ADDDQ36367144-0392C23D-D4B8-4F73-87FE-80C02495A3F5Q36372357-3568C024-E0B4-4ACA-B381-E2457F672E08Q36423166-EE1ECB06-00DB-40F2-82AD-96CA57ACF32CQ36684583-4FB655EF-8AB0-460B-867B-7213857AE66AQ36729450-A8679C20-5473-4C77-8381-BBA6F356A86CQ37076019-E414B367-96F3-4A03-857C-5956BCE126F8Q37301893-48D26AF5-7407-4541-AB56-C70E55AFA99BQ37399436-D80551AF-1D40-415F-BA21-C638829B087DQ37413127-CB5C8136-BF4E-4C6D-9CC4-D9B9834D439FQ37493227-3B856EB1-5EE9-41BF-BD37-00EABC87AC6AQ37857056-A9B9D9DD-B3B4-4DC5-A6ED-3609AC99DF4FQ37914633-D94B6F69-201A-457C-837A-1E1975321842Q37989160-DDD2AA50-7DBD-46BA-8566-D18357B3A9C8Q38083387-FE8EF77D-14DA-4978-929F-B70CB4042105Q38096477-F3118B34-2697-44B6-8523-B5864E70AAA1Q38447668-23207209-1A69-4BB8-8651-F51D9B6E2DBBQ38533017-2D7B88C4-3C22-48AD-A65E-73986FCF23EAQ38635474-02AA4241-FCD0-469B-AE80-4FB152D00F58Q38652256-8E8CE85B-0900-4700-936C-F510C79DAB26Q38701634-086C8AFB-2C63-4E81-AD2C-193B5C7AF242Q38743727-2F09DD39-A124-4619-8B0F-17AABC5000F5Q39356122-A6556957-7DE4-4A1B-93B8-14A5C164F958Q39546437-E3A48419-41C4-4184-9854-DB8FF8FAB7E1Q41544681-9E03B63C-60FB-4DE0-9FDA-AB75760B7AEAQ41706847-5546DFD8-AC7F-4791-9DC0-1AFC10913CCD
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Sorafenib: where do we go from here?
@ast
Sorafenib: where do we go from here?
@en
type
label
Sorafenib: where do we go from here?
@ast
Sorafenib: where do we go from here?
@en
prefLabel
Sorafenib: where do we go from here?
@ast
Sorafenib: where do we go from here?
@en
P2093
P2860
P356
P1433
P1476
Sorafenib: where do we go from here?
@en
P2093
Abby B Siegel
Arthur Magun
Robert S Brown
Sonja K Olsen
P2860
P304
P356
10.1002/HEP.23633
P407
P577
2010-07-01T00:00:00Z